Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Trial Profile

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Exemestane (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Jan 2013 Planned end date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Planned end date changed from 1 Apr 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top